CDKN2A and melanoma: Next, we added cuproptosis-related genes (pyruvate dehydrogenase E1 subunit alpha 1 [PDHA1], cyclin dependent kinase inhibitor 2A [CDKN2A], solute carrier family 31 member 1 [SLC31A1]) to the prognostic signatures to construct a more effective prognostic signature (model2) for melanoma.